The results indicated that the active compounds in FLD might play pivotal roles in anti-NAFLD through the core targets such as albumin (ALB), mitogen-activated protein kinase1 (MAPKI), caspase-3 (CASP3), mitogen-activated protein kinase 8 (MAPK8), and androgen receptor (AR). The gene discussed is MAP3K8; the disease is metabolic dysfunction-associated steatotic liver disease.